9. Outcome of 12-weeks Triple Therapy (TT), including Sofosbuvir (SOF), Ribavirin and Pegylated interferon-Alfa in all non-cirrhotic patients with chronic Hepatitis-C Genotype-3 infection
Nizamuddin1, Ayesha Jamil1, Muhammad Riaz1, Waheed Iqbal2, Fazal Rahim1 and Hasan Raza3
ABSTRACT
Objective: The treatment of hepatitis C virus (HCV) infection is rapidly evolving from interferon and ribavirin which is the standard of care (SOC) for genotype 3-infection, to the most effective Triple therapy by adding Sofosbuvir to the SOC regimen. We assessed the efficacy of Sofosbuvir based triple therapy in new and previously non-responder patients with Hepatitis-C Genotype-3 infection, the most common genot pe infecting Pakistani community.
Study Design: Prospective / multi-center study
Place and Duration of Study: This study was conducted at the Pharmacology De artment, Khyber Girls Medical College, Peshawar Pakistan from October 2015 to April 2016.
Materials and Methods: We recruited a total of 75 patients and were assigned into three groups (Group A, B, C). Group-A as treatment naive, group-B as non-responder to conventi nal interfer n plus Ribavirin and group-C as non-responder to peg-interferon and ribavirin. Sofosbuvir based triple therapy was given for 12-weeks. The primary end point was Sustained Virological Response12 (SVR12), which is H V-RNA level<40IU/ml at 12weeks after completion of therapy.
Results: Among75 patients, male-female ratio was n=51and n=24respectively.Each group has25-cases. Rate of SVR12 was 100%(n=25/25) in group-A, 92%(n=23/25) n group - B and 88%(=22/25) in group-C.
Conclusion: Our findings suggest that addition of sofosbuvir to the standard therapy results in the better achievement of SVR in new and previously n n-resp der cases with Chronic Hepatitis-C genotype-3 infections. Key Words: Chronic hepatitis-C, triple therapy, S f sbuvir.
Citation of articles: Nizamuddin, Jamil A, Riaz M, Iqbal W, Rahim F, Raza H. Outcome of 12-weeks Triple Therapy (TT), including Sofosbuvir (SOF), Ribavirin and Pegylated interferon-Alfa in all non-cirrhotic patients with chronic Hepatitis-C Geno ype-3 infection. Med Forum 2017;28(7):40-43.